Monday’s agreement comes days after PTC discontinued the development of another asset, utreloxastat, due to disappointing ...

After extending its review period to evaluate additional submissions, the FDA ultimately denied Applied Therapeutics’ ...

The FDA last week announced that it is looking into the safety of bluebird bio ’s gene therapy Skysona (elivaldogene ...

At the conference, AstraZeneca and Daiichi Sankyo will present their case for Dato-DXd in NSCLC, while BioNTech and Merus ...

Despite hotly debated biomarkers and failed or delayed confirmatory trials, the accelerated approval program has a track ...

Emboldened by technological advances and a deeper knowledge of glioblastoma, Merck, Kazia Therapeutics, CorriXR Therapeutics ...

Projected to be worth over $38 billion in the global healthcare market by 2032, AI simulations have the potential to ...

“The NRDL inclusion of AUGTYRO significantly expands access to patients living with ROS1+ NSCLC in China to a new treatment option with promising durability. We look forward to launching AUGTYRO by ...

Sensei Biotherapeutics (Nasdaq: SNSE) is a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients. Through its TMAb™ (Tumor ...

Eli Lilly topped the list of the 20 biggest pharmas by market cap with a more than 39% improvement year-to-date in its share ...

Trump is rounding out his health cabinet with another controversial figure: one of the authors of the Great Barrington ...

Despite the “unfortunate” failure, William Blair analysts do not believe that the utreloxastat readout will heavily affect ...